Cardinal Health Inc. ($CAH) Stock Forecast: Up 5.2% Today

What is Cardinal Health Inc.?

Cardinal Health (CAH) operates as a pharmaceutical distributor, specializing in the distribution of pharmaceutical and medical products. The company has recently exhibited notable bullish momentum in the stock market.

Why is Cardinal Health Inc. going up?

CAH stock is up 5.2% on Jan 13, 2026 15:25

• Following an upward trend, Cardinal Health's stock witnessed a surge subsequent to the company's revision of its fiscal-year guidance and its forecast of specialty revenue surpassing $50 billion for 2026.
• The optimistic projections for 2026, fueled by successful strategic moves like alterations in Medicare Drug Prices and alliances with Publix Super Markets, played a significant role in driving the stock's upward trajectory.
• Launches such as the ContinuCare™ Pathway program for diabetes supply management, coupled with strong performance across operational sectors, underscored the company's substantial strategic advancement.
• In essence, Cardinal Health's favorable forecasts and strategic endeavors have bolstered investors' confidence, thereby propelling the bullish trend in the stock market.

CAH Price Chart

CAH Technical Analysis

CAH News

Cardinal Health Stock Jumps on Guidance Raise. Why 2026 Will Be a Good Year.

Cardinal Health's stock rose significantly after the company raised its fiscal-year guidance. The pharmaceutical distributor also projected over $50 billion in specialty revenue for 2026, indicating strong growth in its specialized medicine sector. This optimistic outlook suggests that 2026 will be a good year for Cardinal Health.

https://www.barrons.com/articles/cardinal-health-stock-earnings-guidance-d66399ee?gaa_at=eafs&gaa_n=AWEtsqeEi7MvDqsX7E0ieyvpI5BUiV8HxtUey2Fe63gwVKcjTZIhXiWYgAp0&gaa_ts=69665214&gaa_sig=adG6yhggz5P37SkQBTKWEldeBghqjG7KLZE6jZ_Pkco9alypdyXIXb5UJv02l3FppYrgeitsN2FKD0i5V0b56g%3D%3D

Cardinal Health Inc Updates Fiscal 2026 Outlook and Strategic Initiatives

Cardinal Health Inc. raised its fiscal 2026 earnings per share outlook to at least $10.00 and anticipates specialty revenues to exceed $50 billion. The company highlighted strategic growth initiatives including successful Medicare Drug Price changes, the introduction of ContinuCare™ Pathway for diabetes, and an expanded pharmacy network through a partnership with Publix Super Markets. These updates were provided at the J.P. Morgan Healthcare Conference.

https://www.tradingview.com/news/tradingview:7f0041e7f1968:0-cardinal-health-inc-updates-fiscal-2026-outlook-and-strategic-initiatives/

(CAH) Cardinal Health Expects Fiscal 2026 Adjusted EPS At Least $10, vs. FactSet Est of $9.86

Cardinal Health (CAH) announced that it expects its fiscal year 2026 adjusted Earnings Per Share (EPS) to be at least $10, surpassing FactSet's estimate of $9.86. This updated outlook was published on January 13, 2026, at 07:03 am EST by MT Newswires. The company specializes in the distribution of pharmaceutical and medical products.

https://www.marketscreener.com/news/cah-cardinal-health-expects-fiscal-2026-adjusted-eps-at-least-10-vs-factset-est-of-9-86-ce7e58dbdc8ef725

Cardinal Health forecasts $50B specialty sales, expands diabetes program

Cardinal Health has raised its fiscal year 2026 non-GAAP diluted EPS outlook to at least $10.00 and expects Specialty revenues to exceed $50 billion, demonstrating a strong strategic growth plan. The company also announced expanded initiatives, including over 30% revenue growth anticipated in BioPharma Solutions and the launch of the ContinuCare™ Pathway program for diabetes supply management, partnering with Publix Super Markets Inc. Cardinal Health highlights successful navigation of Medicare Drug Price Negotiation changes and continued investments in product innovation.

https://www.stocktitan.net/news/CAH/cardinal-health-raises-fiscal-2026-outlook-and-highlights-strategic-es8t7aihppzj.html

Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation

Cardinal Health has raised its fiscal year 2026 non-GAAP diluted earnings per share outlook to at least $10.00, up from a previous range of $9.65 to $9.85, driven by strong performance across its operating segments. The company also projects its Specialty revenues to exceed $50 billion in fiscal 2026, representing a 16% compounded annual growth rate over three years. Additionally, Cardinal Health confirmed the successful transition of manufacturer distribution service agreements for pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation Program and introduced the ContinuCare™ Pathway program to simplify diabetes supply management.

https://www.prnewswire.com/news-releases/cardinal-health-raises-fiscal-2026-outlook-and-highlights-strategic-progress-during-jp-morgan-healthcare-conference-presentation-302659259.html

Trending Today

Internet Computer ($ICP) Crypto Forecast: Down 5.0% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 7.7% Today

Mobileye Global ($MBLY) Stock Forecast: Down 7.0% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 5.4% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 10.7% Today

Intel Corporation ($INTC) Stock Forecast: Down 17.6% Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Up 4.9% Today

Sonos Inc. ($SONO) Stock Forecast: Down 5.2% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 8.0% Today

Leggett & Platt Incorporated ($LEG) Stock Forecast: Down 5.2% Today

Cardinal Health Inc. Price History

04.03.2025 - CAH Stock was down 5.6%

• CAH stock fell by 1.14% in the latest trading session.
• This downward movement could be related to market volatility or negative factors affecting the healthcare industry.
• Investors may be responding to worries about regulatory adjustments or changes in consumer healthcare demands.
• Traders should stay updated on company-specific updates and broader market patterns when considering CAH's stock.

05.00.2026 - CAH Stock was up 1.0%

• The strategic shift towards specialty pharmaceutical distribution and healthcare services by Cardinal Health is positively impacting its growth trajectory.
• The overall bullish sentiment in the pharmaceutical industry, as evidenced by the projected growth of the Palliative Care Market, is likely contributing to CAH's upward movement.
• Analysts lowering price targets for competitors like Cencora (COR) while maintaining a Neutral rating may be diverting investor attention towards Cardinal Health, driving its stock price higher.
• The recognition of Cardinal Health as a stable long-term investment due to its essential role in the healthcare supply chain and consistent demand for medications is attracting investors seeking steady growth opportunities.

02.11.2025 - CAH Stock was down 3.0%

• The bearish movement in Cardinal Health's stock today could be attributed to various factors:
• Despite the company's increased operating earnings, the recent revenue dip might have raised concerns among investors about its growth prospects.
• The acquisition announcement and year-end results reporting might have not met market expectations, leading to a negative sentiment towards the stock.
• The overall market sentiment towards healthcare stocks or specific developments within the healthcare sector could have influenced the bearish movement in CAH's stock price.
• Investors might be reevaluating Cardinal Health's financial stability and growth potential in comparison to other highlighted stocks with strong interest coverage ratios.
• The focus on financial metrics like the Price-to-Earnings ratio and valuation scores in discussions about other companies could have also shifted investor attention away from Cardinal Health, impacting its stock performance negatively.

13.00.2026 - CAH Stock was up 5.2%

• Following an upward trend, Cardinal Health's stock witnessed a surge subsequent to the company's revision of its fiscal-year guidance and its forecast of specialty revenue surpassing $50 billion for 2026.
• The optimistic projections for 2026, fueled by successful strategic moves like alterations in Medicare Drug Prices and alliances with Publix Super Markets, played a significant role in driving the stock's upward trajectory.
• Launches such as the ContinuCare™ Pathway program for diabetes supply management, coupled with strong performance across operational sectors, underscored the company's substantial strategic advancement.
• In essence, Cardinal Health's favorable forecasts and strategic endeavors have bolstered investors' confidence, thereby propelling the bullish trend in the stock market.

08.00.2026 - CAH Stock was down 3.0%

• The recent decline in CAH stock price could be linked to profit-taking by investors following a previous increase in value.
• Although Cardinal Health delivered impressive Q3 earnings that exceeded analyst expectations, market sentiment or profit-related concerns may have driven the stock lower.
• An increased investment by Robeco Institutional Asset Management B.V. initially inspired confidence in the stock, but prevailing market conditions may have overshadowed this development.
• Investor focus on the strong performance and growth potential of McKesson in the healthcare sector may have diverted attention from Cardinal Health, impacting its stock performance unfavorably.

03.09.2025 - CAH Stock was down 3.7%

• Cardinal Health (CAH) may have faced a downward trend due to its underperformance relative to other medical stocks like Arcutis Biotherapeutics (ARQT).
• The subdued performance of CAH in the healthcare industry this year might be linked to the market's negative movement.
• Investors could be turning their attention towards more promising opportunities in the medical field, resulting in a sell-off of CAH shares.
• Contrasting with ARQT's strong showing could have revealed weaknesses in CAH's finances or growth prospects, prompting investors to review their positions and contributing to the bearish trend.

12.07.2025 - CAH Stock was down 7.3%

• There has been bullish options activity indicating positive sentiment from investors, although this did not result in a positive stock movement.
• The company exceeded earnings estimates and raised EPS guidance for 2026, leading to a stock drop potentially linked to concerns about the expiration of the OptumRx contract and its impact on Pharmaceutical segment sales.
• The upcoming release of Q4 earnings may have caused stock price volatility as investors reacted to forecast changes and dividend income strategies.
• A comparison with Adaptive Biotechnologies in the medical sector suggests that market dynamics and company-specific factors could have influenced Cardinal Health's bearish performance despite positive developments.

12.07.2025 - CAH Stock was down 12.2%

• The bearish movement in CAH stock could be attributed to investors' concerns about the upcoming earnings report falling short of expectations.
• Discussion about earning $500 a month from CAH stock might have raised unrealistic expectations among investors, leading to disappointment when the stock did not perform as anticipated.
• A comparison with Adaptive Biotechnologies (ADPT) might have highlighted stronger performance in the medical sector by ADPT, causing some investors to shift their focus away from CAH.
• Overall, the bearish movement in CAH could be a result of a combination of profit-taking, cautious investor sentiment ahead of the earnings report, and comparative underperformance within the sector.

10.05.2025 - CAH Stock was down 0.5%

• The overall market sentiment is bearish today.
• The bearish movement in CAH stock could be attributed to the announcement of a distribution services agreement between Citius Pharmaceuticals and Cardinal Health. This partnership might have raised concerns among investors about potential competition or changes in Cardinal Health's business strategy, leading to a negative impact on CAH stock price.

30.09.2025 - CAH Stock was up 17.6%

• Cardinal Health (CAH) saw a solid uptrend today, with its stock price rising by +1.72%.
• The positive market sentiment towards CAH is driven by expectations of robust Q1 earnings, especially in its Pharmaceutical and Specialty units.
• CAH has consistently outperformed the market over the past 5 years, with an average annual return of 27.8%, attracting investors seeking stable returns in the healthcare sector.
• The favorable expectations for CAH's financial performance and its strong position in the healthcare industry have fueled the uptick in its stock price today.

30.09.2025 - CAH Stock was up 17.4%

• Cardinal Health (CAH) experienced a strong bullish movement today, with its stock price increasing by +1.72%.
• The positive market movement can be attributed to the expectation of double-digit revenue growth in Q1 FY26, primarily driven by the Pharmaceutical and Specialty units.
• Additionally, the company's consistent outperformance in the market over the past 5 years, with an average annual return of 27.8%, has likely contributed to investor confidence and buying interest in CAH shares.
• Overall, the market seems optimistic about Cardinal Health's future prospects, supported by strong financial performance and growth potential in key business segments.

30.09.2025 - CAH Stock was up 13.0%

• The stock of Cardinal Health saw a notable increase following the positive announcement of its first-quarter 2026 earnings. Adjusted earnings outperformed expectations, and sales witnessed a substantial year-over-year growth.
• Cardinal Health's successful performance in Q1 and the upgraded 2026 EPS forecast point towards a widespread expansion and growing profitability across all sectors, fostering investor confidence.
• Investor optimism towards Cardinal Health has been influenced by its consistent market outperformance in the last 5 years, indicating attractive returns for stakeholders.
• Anticipated double-digit revenue growth in the first quarter of fiscal year 2026, especially in the Pharmaceutical and Specialty units, has further heightened investor confidence in the company's future prospects, encouraging a bullish trend in the stock price.